Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2016 | The significance of fulvestrant for hormone receptor-positive advanced breast cancer

Matthew Ellis • 7 Oct 2016
ESMO 2016
Breast Cancer Anastrozole Fulvestrant
FALCON

Matthew Ellis, MB, BChir, PhD, FRCP of Baylor College of Medicine, Houston, TX discusses the significance of fulvestrant for hormone receptor-positive advanced breast cancer. Metastatic breast cancer and in particular hormone receptor-positive advanced breast cancer, is not an immediate death sentence as Prof. Ellis explains. Many patients do well with different endocrine manipulations and with fulvestrant, we have a potential drug to extend the durability of these initial endocrine responses; this is a key result of the FALCON trial (NCT01602380). He explains that the patients responding to fulvestrant had better quality responses, which means that they are not in need of more complicated therapies or chemotherapy.
Recorded at the 2016 annual meeting of the European Society of Medical Oncology (ESMO), held in Copenhagen, Denmark.

More from Matthew Ellis

FALCON trial of fulvestrant for advanced breast cancer: subgroup analysis and overall survival
1:55
FALCON trial of fulvestrant for advanced breast cancer: subgroup analysis and overall survival
Matthew Ellis • 7 Oct 2016
Design and results of Phase III FALCON trial of fulvestrant for advanced breast cancer
2:17
Design and results of Phase III FALCON trial of fulvestrant for advanced breast cancer
Matthew Ellis • 7 Oct 2016

Related Videos

How will SARMs fit into the current breast cancer treatment paradigm?
1:14
How will SARMs fit into the current breast cancer treatment paradigm?
Rafael Grochot • 2 Jul 2026
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
1:35
Phase I/II trial of vosilasarm and endocrine therapy in AR+/ER+/HER2− breast cancer
Rafael Grochot • 2 Jul 2026
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
1:07
HYPORT: does the number of fractions of RNRT impact the typical symptoms experienced?
Sanjoy Chatterjee • 17 May 2026
Design and aim of the HYPORT study in regional nodal breast cancer
1:23
Design and aim of the HYPORT study in regional nodal breast cancer
Sanjoy Chatterjee • 17 May 2026

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.

Cookie Policy (opens in a new tab)
The content of VJOncology is intended for healthcare professionals